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OBJECTIVES: The 21-gene recurrence score assay (RS) (Oncoytpe Dx, Genomic Health, 
Redwood City, CA) is a genomic test guiding adjuvant chemotherapy use in patients 
with early-stage breast cancer. We assessed the association between RS receipt and 
subsequent chemotherapy use and medical expenditures among newly diagnosed 
early-stage breast cancer patients with commercial insurance. We also explored 
whether the effects of RS receipt varied by patient age. METHODS: The 21-gene 
recurrence score assay (RS) is a genomic test guiding adjuvant chemotherapy use 
in patients with early-stage breast cancer. We assessed the association between RS 
receipt and subsequent chemotherapy use and medical expenditures among newly 
diagnosed early-stage breast cancer patients with commercial insurance. We also 
explored whether the effects of RS receipt varied by patient age. RESULTS: RS receipt 
ranged from 40% among women < 45 years to 47% among women 60-64 years (p= 0.54). 
Chemotherapy use declined from 68% among women < 45 years to 37% among women 
60-64 years (p< 0.001). RS receipt was associated with lower adjusted chemotherapy 
use among women < 55 years (age < 45: 61% vs. 73%, p= 0.14; age 45-49: 33% vs. 61%, 
p< 0.001; age 50-54: 36% vs. 55%, p= 0.010), but not among women ≥ 55 years (age 
55-59: 48% vs. 49%, p= 0.83; age 60-64: 41% vs. 40%, p= 0.86). RS receipt also had a larger 
impact on adjusted medical spending among women < 55 years (age < 45: $102,000 
with invasive early-stage BC from 2003 to 2006 were selected from the SEER-Medicare 
linked dataset. Multivariate logistic regression models examined the relationship 
between type of treatment and various independent factors. RESULTS: Overall, 54% 
received BCS+RT, 23% received mastectomy, and 24% received BCS without RT. The 
likelihood of mastectomy or BCS without RT was greater for women with increasing 
age (> 80 vs. 66-69) (AOR, 2.48; 95%CI, 2.26-2.73) and (AOR, 3.19; 95%CI, 2.91-3.50) , stage 
(II vs. I) (AOR, 3.37; 95%CI, 3.15-3.60) and (AOR, 1.30; 95%CI, 1.21-1.39), comorbidity 
(> 2 vs. 0) (AOR, 1.15; 95%CI, 1.05-1.27) and (AOR, 1.39; 95%CI, 1.27-1.52), and of non-
white race vs. white (AOR, 1.30; 95%CI, 1.17-1.44) and (AOR, 1.27; 95%CI, 1.14-1.41). 
The likelihood of mastectomy or BCS without RT was decreased for those who saw 
an oncology vs. general surgeon (AOR, 0.73; 95%CI, 0.62-0.85) and (AOR, 0.52; 95%CI, 
0.45-0.61), lived in metro areas (AOR, 0.68; 95%CI, 0.62-0.75) and (AOR, 0.72; 95%CI, 0.65-
0.79), areas of higher education (AOR, 0.72; 95%CI, 0.67-0.78) and (AOR, 0.78; 95%CI, 
0.72-0.84), and higher income (AOR, 0.89; 95%CI, 0.81-0.97) and (AOR, 0.85; 95%CI, 0.78-
0.92), than women who received BCS+RT. CONCLUSIONS: Treatment for early-stage 
BC is associated with socio-demographic characteristics and factors such as stage, 
surgeon specialty, and comorbidities, perhaps reflecting a notion that RT is not well 
tolerated among the elderly. Treatment could be improved by ensuring all patients 
are informed of, have access to, and receive full treatment, unless meeting specific 
treatment guideline criteria for exemption.
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OBJECTIVES: To describe how US payers use heterogeneity of treatment effect 
(HTE) evidence when formulating coverage policies for oncology drugs. METHODS: 
A qualitative approach using semi-structured in-depth interviews with 15 payers 
was used in to answer our question. An interview guide was developed based on 
theory and pilot interviews. Themes that emerged from content analysis were sum-
marized. RESULTS: US payers understand the importance of using HTE evidence in 
oncology. However, the utility of such evidence to inform real-world coverage deci-
sion making is questionable. The Food and Drug Administration (FDA) label is the 
most overwhelming determinant of whether HTE evidence gets incorporated into 
a coverage policy. If not in the FDA label, payers find it difficult to use HTE evidence 
due to the inability to precisely differentiate responders from non-responders and 
the logistical difficulty to operationalize HTE. All payers reported that subgroup 
analyses on randomized clinical trial data are the most trusted source to estab-
lish HTE evidence. In addition to the FDA label, payers also consider treatment 
guidelines, quality/magnitude of HTE evidence, availability of effective alternative 
substitutes, treatment line, cancer aggressiveness, and politics. When a biomarker 
and a companion diagnostic is involved, the degree to which HTE evidence is incor-
porated into coverage policies will also depend on the clinical and analytic validity 
of the test and the ability to accurately and pragmatically distinguish responders 
from non-responders. Most payers indicated that if oncologists steer treatments to 
patients who are expected to benefit, there would not be a need for a policy; how-
ever, if a physician practice gap is evident, a coverage policy that incorporates HTE 
would be crucial. CONCLUSIONS: Payers’ oncology coverage decisions are impacted 
by a myriad of factors, especially the FDA label. Payers require more definitive HTE 
evidence in order to make more efficient coverage decisions.
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OBJECTIVES: The patient centered medical home (PCMH) is a model of delivering 
primary care with features such as comprehensive, coordinated, continuous and 
accessible care. The high cost and intensive long-term care requirements of cancer 
survivors makes this population a perfect candidate for the PCMH model of care. The 
objective of this study is to determine if access to a PCMH is associated with lower 
healthcare costs and utilization among cancer surviviors. METHODS: The study 
population was drawn from the 2008-2012 data of the Medical Expenditure Panel 
Survey. The final sample included 7,081 adults with a history of at least one type of 
cancer diagnosis other than non-melanoma skin cancer (“cancer survivors”), who 
reported having a usual source of care (USOC), were eligible for the required sup-
plemental questionnaire on access to care and were in-scope throughout the survey 
year. A subject’s USOC is defined as a PCMH based on the American Association of 
Pediatrics’ concept of a medical home and published literature. Healthcare utiliza-
tion included the number of emergency department (ED) visits, hospital admissions, 
office-based visits and prescription medications, which were analyzed using nega-
tive binomial regression models. Medical expenditure was analyzed using general-
ized linear model with gamma distribution and log link function. RESULTS: Cancer 
survivors with a PCMH had a lower incidence of ER visits (Incidence Rate Ratio (IRR) 
= 0.77, 95% CI: 0.66-0.90) and consumed fewer prescription medications (IRR= 0.93, 
95% CI: 0.88-0.99). There was no association between access to medical homes and 
outpatient (IRR= 0.96, 95% CI: 0.90-1.03) or inpatient (IRR= 1.06, 95% CI: 0.90-1.24) 
visits and total medical expenditure (β = -0.05, 95% CI: -0.17-0.07). CONCLUSIONS: 
Access to a PCMH was associated with reduced ED visits and prescription drugs use 
among cancer survivors. However, no difference in inpatient or outpatient visits, or 
overall medical expenditures were found.
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effectiveness(3.2). Majority of oncologists noted cost of cancer drugs (63%) and patient’s 
out-of-pocket drug costs (79%) as somewhat/quite-a-bit/a lot influencing their cancer 
treatment recommendations; 90% reported (as somewhat/quite-a-bit/a lot) that cost of 
cancer drugs is expected to play a more significant role in influencing their treatment 
recommendations, over the next five years; 78% reported (as somewhat/quite-a-bit/a 
lot) that payer reimbursement policy limited their ability to offer certain cancer therapy 
to patients; 27% noted the increased use of cost-effectiveness data among payers 
when deciding reimbursement as neither-positive-nor-negative/somewhat negative/
very negative. CONCLUSIONS: In this cohort of oncologists across the US, a signifi-
cant proportion identified cancer drug cost and patient out-of-pocket costs as factors 
influencing their treatment recommendations. The respondents concurrently ranked 
drug cost-effectiveness lower than drug efficacy, safety/tolerability and impact on 
quality-of-life while addressing “value of new cancer drugs”. Impact of these oncologist 
perceptions on day-to-day clinical practice behavior warrants scrutiny.
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OBJECTIVES: To compare cancer information (CI) seekers’: a) most recent CI-seeking 
experiences, and b) self-efficacy (SE) in seeking CI across demographics, healthcare 
access, and health status. METHODS: Cross-sectional, retrospective study was con-
ducted on a representative, non-institutionalized sample of the U.S. population using 
HINTS-4 Cycle-2 data. Study sample consisted of individuals who looked for CI from 
any source (N= 1097). Response categories for all CI-seeking experience except for 
‘concern about quality of information’ were dichotomized as ‘yes’ and ‘no’. Similarly, 
response categories for self-efficacy in seeking CI were combined to form ‘low SE’, 
‘moderate SE’, and ‘high SE’. Chi-square goodness-of-fit test was applied to all vari-
ables with significance level of 0.05. Cross tabulations, Chi-square analyses were 
conducted, and weighted percentages were computed using SAS® version 9.3. Results 
with p≤ 0.05 were considered statistically significant. RESULTS: Greater proportion 
of CI seekers had characteristics as being female, Non-Hispanic White, some college 
degree, higher annual income, married, employed, having insurance, having a regu-
lar provider, without personal cancer history, with family history of cancer, or with 
‘excellent’ or ‘very good’ current health. Effort required to seek CI differed significantly 
across age, race/ethnicity, education, annual income, marital status, occupation, and 
personal cancer history. Feeling frustrated while seeking CI differed significantly 
across age, annual income, marital status, and personal cancer history. CI seekers’ 
concern about quality of information differed significantly across annual income, 
insurance, and personal cancer history. Difficulty in understanding information dif-
fered significantly across insurance. Individuals’ self-efficacy in seeking CI did not 
differ significantly across any study variables. CONCLUSIONS: Generally, CI-seeking 
experiences are likely to vary with age, race/ethnicity, education, annual income, 
occupation, marital status, and personal cancer history. Findings of this study may 
be useful in improvising current health communication interventions and to develop 
messages that are easily accessible and comprehendible by the American public.
PCN169
AN ANAlysIs of oNColoGy DRuG fINANCING IN HoNG koNG
Sun D, Duttagupta S
CBPartners, New York, NY, USA
OBJECTIVES: The objective of this study was to analyse the financing options for 
oncology drugs in Hong Kong and estimate their time to reimbursement compared 
to other countries. METHODS: This study analysed the time to first inclusion of 
oncology drugs in the Samaritan Fund (based on the most recent SF publication) 
and compared to the time to reimbursement in countries with a similar GDP per 
capita, including Taiwan, Australia, the UK and the USA. Time to reimbursement 
was defined as the date of NHI formulary inclusion in Taiwan, publication of PBAC 
decision in Australia, publication of NICE Final Appraisal in the UK and FDA approval 
in the USA. RESULTS: Currently, only select high-cost oncology drugs are covered 
under the safety net (Samaritan Fund (SF) or Community Care Fund) by the Hospital 
Authority in Hong Kong. Of 9 assessed drugs that are currently covered under the 
SF, the reimbursement coverage of all 9 drugs in Hong Kong lagged behind Taiwan, 
Australia, the UK and the USA, from months to years. On average, the reimburse-
ment coverage of oncology drugs under SF in Hong Kong was 51.9 weeks behind 
the USA, 42.8 weeks behind Australia, 30.4 weeks behind the UK and 20.6 weeks 
behind Taiwan. These numbers were similar to the median reimbursement interval 
between Hong Kong and the USA, Australia, the UK, and Taiwan, which were 45, 
38, 32 and 17 weeks, respectively. CONCLUSIONS: The reimbursement coverage of 
oncology drugs is still limited and significantly delayed in Hong Kong compared to 
other countries with a similar GDP per capita. It not only lags behind western devel-
oped countries, like the USA, the UK and Australia, but also behind its neighbouring 
Asian country, Taiwan. There is therefore an urgent need for innovative solutions by 
the Hospital Authority to deliver access solutions for critical treatments.
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vs. $130,800, p= 0.046; age 45-49: $75,700 vs. $104,600, p= 0.001; age 50-54: $78,100 vs. 
$91,400, p= 0.059) than women ≥ 55 years (age 55-59: $87,100 vs. $91,600, p= 0.61; age 
60-64: $78,300 vs. $83,100, p= 0.48). CONCLUSIONS: Among adult women with com-
mercial insurance, RS receipt was associated with less use of adjuvant chemotherapy 
and lower medical spending among women < 55 years old but not among women 
55-64 years old.
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OBJECTIVES: Despite scientific advances, pricing for many cancer medicines 
remains based upon the content of the delivery form (e.g. infusion vial), and size 
of patient. This can cause uncertainty of budget impact & cost effectiveness, and is 
not easily related to the value delivered. New methods which bring greater certainty 
of budget impact, cost effectiveness, and value should be evaluated. METHODS: 
25 pricing schemes were researched, and two novel pricing models developed 
applicable to a range of countries were evaluated. The first approach is DRG-based 
pricing; DRG coding is used by most healthcare systems & is intervention specific. 
The second method is licensing the medicine for a specific cancer; the purchaser 
pays a licence fee for treatment, based on outcomes. RESULTS: Current pricing 
approaches are usually discounts or rebates, charged in the same manner as current 
pricing (e.g. mg/Kg). While associated with low service burden and lower costs, this 
does not reduce uncertainty or bring a closer relationship to value. Utilising new 
approaches, such as DRG pricing or licencing for medicines enables accurate predic-
tion for budget impact, enables price to be disease specific & based on value. Both 
novel methods could be developed for metastatic melanoma, NSCLC & breast cancer. 
Both methods are outcomes based (e.g. per month of progression free survival or 
overall mean or median survival), and enable purchasers to utilise medicines at a 
fixed price irrespective of weight/size of the patient, or vial size, priced according to 
value for the specific disease. Both methods would require a change in the coding 
and purchasing method for medicines by healthcare providers. CONCLUSIONS: 
New mechanisms including DRG or licensing could bring greater certainty of budget 
impact & value for specific illnesses. These methods should be piloted by healthcare 
systems to ensure practical application brings benefits, without high service burden.
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OBJECTIVES: Manufacturers are developing an increasing number of high cost ther-
apies, especially those in oncology, infectious disease, and rare/ ultra-rare diseases. 
In recent years there has also been an increase in the role of ‘nontraditional’ payers 
such as healthcare reinsurers, both in the US and globally, in biopharmaceutical 
funding and reimbursement. We assessed the global role of health care reinsurance 
as an alternate funding model for high cost treatments, including opportunities 
for manufacturers to partner with reinsurance to expand the market for innova-
tive therapies. METHODS: We conducted a literature search, scanned secondary 
resources and conducted informal interviews with healthcare reinsurance execu-
tives and other internal experts to identify key trends in reinsurance, including case 
studies and funding mechanisms. RESULTS: In the US, reinsurance is prevalent 
in the form of stop-loss insurance, which is typically purchased by employer self-
funded health plans and small group first-dollar coverage insurers, which represent 
approximately 60% of the privately insured population. Stop-loss carriers (SLCs) play 
a role in reimbursing therapies when costs exceed pre-determined ‘thresholds’ or 
‘attachment points’. In these cases, SLCs determine whether coverage criteria are 
met by examining FDA labeling, first-dollar insurer plan policies, and site of care 
(in-network vs. out-of-network providers). In Asia, reinsurance has emerged as a 
vehicle to expand the insured market for biopharmaceutical products. In China for 
example, multinational manufacturers have partnered with reinsurance carriers 
to reinsure private health insurance carriers, in effect, expanding coverage for high 
cost therapies. CONCLUSIONS: In the US and globally, manufacturers of high-cost 
treatments must proactively recognize and plan for potential roles of reinsurance 
in reimbursement of their products, especially in certain scenarios where reinsur-
ance could present a significant barrier to uptake or increases risk of non-payment, 
and where reinsurance may be leveraged to expand access to high cost treatments.
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OBJECTIVES: To assess the perception of value of cancer drugs among oncologists 
in the U.S. METHODS: A cross-sectional survey of oncologists was conducted online 
in August-September 2014 using a large panel of physicians in the US; specifically, 
medical oncologists and hematologist/oncologists currently managing > = 20 patients 
in their practice and had > = 2 years of practice experience were randomly selected 
for survey participation to be geographically representative. The survey assessed 
oncologist perception of “value of new cancer drugs”, the factors influencing their 
recommendation of cancer treatments to patients in clinical practice and other ele-
ments such as payment reforms and practice characteristics. Descriptive statistics 
are reported. RESULTS: 231 oncologists participated in the survey (medical oncolo-
gists:32%, haemato-oncologists-68%). Geographic distribution: Northeast-29%/
Midwest-23%/South-32%/West-16%; 53% and 47% were from hospital and private-
practice settings respectively. Oncologist ranking of product attributes concerning 
“value of new cancer drugs” (scale:1(most important)-4(least important)) was (mean 
scores): clinical efficacy(1.4), Safety/tolerability(2.7), impact on quality of life(2.7), cost-
